| pubmed-article:2285025 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2285025 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2285025 | lifeskim:mentions | umls-concept:C0027950 | lld:lifeskim |
| pubmed-article:2285025 | lifeskim:mentions | umls-concept:C0028116 | lld:lifeskim |
| pubmed-article:2285025 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2285025 | lifeskim:mentions | umls-concept:C0085416 | lld:lifeskim |
| pubmed-article:2285025 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:2285025 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:2285025 | pubmed:dateCreated | 1991-3-15 | lld:pubmed |
| pubmed-article:2285025 | pubmed:abstractText | Nisoldipine inhibits calcium (Ca++) influx in human neutrophils: Preincubation with the dihydropyridine, nisoldipine (1.5 microM) resulted in a 30% decrease in [45]Ca++ influx during formyl-methionine-leucine-phenylalanine (FMLP) stimulation in primed as well as resting cells. Although the drug does not inhibit Ca++ dependent effector functions elicited by FMLP, e.g. superoxide (O2-) production, it inhibits FMLP priming, a phenomenon that is independent of extracellular Ca++. Nisoldipine exhibited a narrow dose response with an ED50 of ca. 1 microM and total inhibition of primed O2- response at 1.5 microM. Nisoldipine (1.5 microM) also abolished the incremental rise of Ca++i in primed neutrophils stimulated with FMLP. The dissociation of nisoldipine inhibitory effects on cell effector function and Ca++ transport were corroborated in studies with neutrophils stimulated with influenza virus and phorbol myristate acetate (PMA), stimuli which do not exhibit an extracellular Ca(++)-dependence in their elicited responses. Unlike in FMLP-stimulated cells, nisoldipine reduced influenza virus and PMA initiated respiratory burst, indicating that this drug has inhibitory effects on neutrophil function independent of its effect on Ca++ metabolism. Possible sites of action are postulated at phospholipase A2 or calmodulin-regulated activities. Caution is thus required in interpreting the effects of dihydropyridine on cell function, when the drug is used at micromolar concentration. | lld:pubmed |
| pubmed-article:2285025 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2285025 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2285025 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2285025 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2285025 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2285025 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2285025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2285025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2285025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2285025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2285025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2285025 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2285025 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:2285025 | pubmed:issn | 0065-4299 | lld:pubmed |
| pubmed-article:2285025 | pubmed:author | pubmed-author:TauberA IAI | lld:pubmed |
| pubmed-article:2285025 | pubmed:author | pubmed-author:HartshornK... | lld:pubmed |
| pubmed-article:2285025 | pubmed:author | pubmed-author:KarnadA BAB | lld:pubmed |
| pubmed-article:2285025 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2285025 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:2285025 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2285025 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2285025 | pubmed:pagination | 79-85 | lld:pubmed |
| pubmed-article:2285025 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2285025 | pubmed:meshHeading | pubmed-meshheading:2285025-... | lld:pubmed |
| pubmed-article:2285025 | pubmed:meshHeading | pubmed-meshheading:2285025-... | lld:pubmed |
| pubmed-article:2285025 | pubmed:meshHeading | pubmed-meshheading:2285025-... | lld:pubmed |
| pubmed-article:2285025 | pubmed:meshHeading | pubmed-meshheading:2285025-... | lld:pubmed |
| pubmed-article:2285025 | pubmed:meshHeading | pubmed-meshheading:2285025-... | lld:pubmed |
| pubmed-article:2285025 | pubmed:meshHeading | pubmed-meshheading:2285025-... | lld:pubmed |
| pubmed-article:2285025 | pubmed:meshHeading | pubmed-meshheading:2285025-... | lld:pubmed |
| pubmed-article:2285025 | pubmed:meshHeading | pubmed-meshheading:2285025-... | lld:pubmed |
| pubmed-article:2285025 | pubmed:meshHeading | pubmed-meshheading:2285025-... | lld:pubmed |
| pubmed-article:2285025 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2285025 | pubmed:articleTitle | Effect of nisoldipine on priming and activation of the human neutrophil respiratory burst. | lld:pubmed |
| pubmed-article:2285025 | pubmed:affiliation | William B. Castle Hematology Research Laboratory, Boston City Hospital, MA. | lld:pubmed |
| pubmed-article:2285025 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2285025 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:2285025 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
